The central nervous system (CNS) represents an important target for HIV infection during multiple stages of the disease: early, after invasion of the host, acting as a viral reservoir; lately, subverting its function and causing peripheral neuropathies and neurocognitive disorders; and lastly, during the final stage of NeuroAIDS, triggering opportunistic infections, cancers, and dementia. Highly active antiretroviral therapy, a combination of drugs that inhibits enzymes essential for HIV replication, can reduce the viremia and the onset of opportunistic infections in most patients, and prolong the survival. Among the limits of the current treatments the most noticeable is the inability to eradicate HIV-infected cells, both, limiting the time frame in which antiretroviral therapies initiated after exposure to HIV can prevent infection, and allowing replication-competent virus that persists in infected cells to emerge rapidly after the cessation of treatments. Many strategies are currently under evaluation to improve HIV treatment, unfortunately more than 98% of drug candidates for CNS disorders never make it to the clinic; here in we report how nanoformulated strategies might be adapted and applied to the field of CNS–HIV infection.

Keywords: CNS–HIV infection, NeuroAIDS, nanoformulated HAART
Table 1 | HAART currently in use in the clinical practice.

| Classes of drugs                        | Phase of the retroviral life-cycle targeted                                                                 |
|----------------------------------------|------------------------------------------------------------------------------------------------------------|
| Entry inhibitors (EIs)                 | They interfere with binding, fusion, and entry of HIV-1 to the host cell                                  |
| CCR5 receptor antagonists (CCR5RAs)    | They bind to the CCR5 receptor on the surface of the T-Cell and block viral attachment to the cell. If HIV cannot attach to the cell, it cannot gain entry to replicate |
| Nucleoside reverse transcriptase inhibitors (NRTIs) and nucleotide reverse transcriptase inhibitors (NtRTIs) | They inhibit reverse transcription by being incorporated into the newly synthesized viral DNA strand as faulty nucleotides; they both act as competitive substrate inhibitors |
| Protease inhibitors (PIs)              | They inhibit viral assembly by inhibiting the activity of protease, an enzyme used by HIV to cleave nascent proteins for the final assembly of new virions |
| Integrase inhibitors (IIs)             | They inhibit the enzyme integrase, which is responsible for integration of viral DNA into the DNA of the infected cell |
| Maturation inhibitors (MIs)            | They inhibit the last step in gag processing in which the viral capsid polyprotein is cleaved, thereby blocking the conversion into mature capsid protein |

brain function. To understand the correlates in terms of neuro-protection, neuroinflammation, and neurodegeneration processes many preclinical models have been developed, such as: HIV transgenic rat (i.e., tg rat from Reid et al., 2001), or mice (i.e., gp 120 tg mice from Toggas et al., 1994), but also those obtained by injection of HIV proteins (i.e., gp 120 from Sundar et al., 1991; or Tat and Bansal et al., 2000), or HIV-infected macrophages into the brain of mice (Anderson et al., 2003). The most studied signaling pathways include, among others, the GSK3β, CDK5, ERK, Notch, p38, and INK cascades. For instance, it is noteworthy that many mitogen-activated protein kinases are pivotal during acute, asymptomatic, and terminal infection: some of them seems to promote cell growth and differentiation in response to initial infection (i.e., ERK), whereas others are associated to growth arrest, apoptosis, and oncogenic transformation during AIDS. Those data might explain some peculiar characteristics of the HIV–CNS infection: in contrast to HIV-infected CD4+ T cells, infection in brain macrophages and microglial cell lines leads to an extended life span and elevated survival against apoptotic stresses (Chugh et al., 2007), and only during terminal infection, when there is resurgent virus replication, the balance favors neuronal death (i.e., via activation of JNK and p38) reflecting a failure to maintain homeostasis in the CNS (Barber et al., 2004) with the consequent motor and cognitive impairments.

DEVELOPING STRATEGIES

Many strategies are currently under evaluation to improve HIV treatment, but a relatively small number are primarily dedicated to the alleviation of neurological complaints or the control of NeuroAIDS, and unfortunately more than 98% of drug candidates for CNS disorders never make it to the clinic (Pardridge, 2003). Herein are a couple of examples picturing how researches, initially conducted for neoplastic, neurodegenerative, or epileptic disorders, on specific pathways and delivery systems, might be adapted and applied to the field of CNS–HIV infection (see Figure 1).

INNOVATIVELY TARGETED PATHWAYS

Discovered in 1898, mitoguazone (MGBM) had been investigated but abandoned as an anti-cancer drug, recently it was found to cause selective loss of CD16+ HIV-infected cells, specifically by blocking osteopontin needed to transform a circulating macrophage into a CNS/resident one. MGBG although ineffective in reducing HIV viremia, does appear to shut down viral evolution by selectively killing recent migrants macrophages rather than resident cells, and to be safe over the long-term treatment in AIDS patients (Jeymohan et al., 2009).

The manipulation of IFNα and IFNγ APOBEC pathways could prevent HIV invasion of CNS because of the potent intrinsic immunity exerted by the expression of APOBEC3G gene in microvascular endothelial cells (Argyris et al., 2007). This gene code for proteins possessing cytidine deaminase activity and allow the BBB to actively neutralize the effects of viral infectivity factors (Vif), which are essentials for viral entry and spread into the CNS (Jeong et al., 2008).

NK-1, also known as Substance P, was the first neuropeptide discovered in 1931, it is widely distributed in the central and peripheral nervous system where it functions as a potent mediator of immunoregulation. Agonists to NK-1 receptor potently inhibit both in vitro and in vivo HIV replication in human macrophages, apparently down regulating CCR5 (Jeymohan et al., 2009).

Initially recognized, and extensively studied as a promising target for anti-cancer therapies because of its role during tumorigenesis, the PI3K/Akt cell survival pathway became a target for anti-HIV treatment after the observation that PI3K inhibitors (such as wortmannin and LY294002) or Akt inhibitors (such as miltefosine), both able to cross the BBB, contrast the cytotoxic effect exerted by Tat proteins over macrophage/microglial cells, and make them again susceptible to cell death following an apoptotic stimulus (Chugh et al., 2007, 2008). Most interestingly PI3K/Akt inhibitors proved to be effective without harming uninfected cells and therefore experimental data as far available support their possible use for HIV-therapy and targeting of long-lived viral reservoirs.

NANOFORMULATED HAART

Nanoformulated HAART essentially manipulates the immune system for therapeutic purposes by using synthetic or biological nanoengineered drug carriers. Those nanoformulated drugs have been proven to be efficient delivery vehicles for a wide range of therapeutic agents, and can be easily injected in the blood
circulation or virtually into any site of the brain with minimal invasiveness. Major concerns to this therapeutic approach are the choice of drug administration (systemic or local) and consequently the residence in the systemic blood circulation, or in the brain tissue adjacent to topic injection, the drug loading efficiency, and the burst release effect. Furthermore, many other question marks are still to be answered, or even formulated.

Concerning synthetic carriers, hyaluronic acid, a linear polysaccharide composed of alternating d-glucuronic acid and N-acetyl-d-glucosamine units, because of its immunoneutrality, has been proposed as a biocompatible and biodegradable biomaterial for tissue engineering, and in drug delivery systems into the CNS: particularly appealing would seem the opportunity to produce drug-incorporated hyaluronic acid nanoparticles (Jeong et al., 2008). As well monocytes, because of their abilities to move drugs inside the cells have advantages as a depot for HAART, but also they might improve compliance as drugs can be released from cells for periods up to weeks or longer. Nevertheless, further application of biological nanoengineered drug carriers will require optimization of nanoparticles uptake, deeper knowledge of their kinetics across the BBBs, and more sophisticated imaging systems to track migration of monocyte–macrophages to the brain and target the delivery of specific therapeutics (Jeymohan et al., 2009).

NEUROPROTECTIVE STRATEGY

Beside compounds aimed at control the virus, others try to treat the effects of the underlying neuroinflammation and neurodegeneration mechanisms, and might provide a beneficial supplement to HAART.

Neurotoxicity is mainly mediated through glutamate production, which is triggered by NMDA subtypes of glutamate receptors, and correlated to caspase activation and subsequent neuronal apoptosis (Erdmann et al., 2006); accordingly, pharmacologic inhibition of glutaminase directly correlate to neuronal survival (Tian et al., 2008). Those insights support the hypothesis that inhibition of glutamate production by blocking mitochondrial glutaminase activity may clinically prevent neurotoxicity during HIV-1 infection.

Taken together the GSK3β, CDK5, JNK, and p38 signaling pathways are important regulators of neurotoxicity, being responsible for synaptic and dendritic damage to pyramidal neurons, loss of immunoreactive neurons, and demyelination. GSK3β inhibitors (i.e., lithium, valproic acid) as well as CDK5 inhibitors (i.e., roscovitine) seems to protect neuronal integrity and plasticity (Crews et al., 2009), while JNK- and p38-inhibitors (i.e., minocycline) may prevent neuronal death (Lin et al., 2001; Bozyczko-Coyne et al., 2002) each of those target holds promise for the development of treatment strategies to ameliorated the neuropathological effects exerted by HIV proteins (Tat, Vif, etc.).

CONCLUSION

Combinations of drugs work better and longer than seen previously, patients benefit demonstrably from the magnitude and duration of viral suppression, and require more and more symptomatic treatment of NeuroAIDS cognitive impairment.
However HAART is very demanding for patients, non-adherence can lead to therapeutic failure, and in addition drug resistance is a continuing problem; therefore, the need for improved drug and delivery systems, but also an interest for adaptive treatment strategies and mathematical modeling to manage structured treatment interruptions (Rosenberg et al., 2007), have been outlined by many researchers. To this regard a tight collaboration with industry is strictly required and introduces a new set of challenges such as: (1) circulation of promising ideas, often just developed with university grants, (2) protection of intellectual property and patent rights, (3) fund-raising opportunities for start-ups during preclinical researches on novel compounds, until (4) identification of potential blockbusters appealing to Big Pharma companies for introduction in the market and their clinical exploitation.

Finally, current criteria for initiation of HAART do not consider CNS outcomes as a benchmark of efficacy, thus establishing CNS-based criteria for initiation of protocols should be the ultimate goal not only for therapeutic but also for neuroprotection strategies; as recently stated by Jeymohan et al. (2009) on behalf of the NeuroAIDS research participants these priorities should be seen as a template for future growth of the field and its long-term impact.

ACKNOWLEDGMENTS

We are grateful to Mrs. Gloria Mogren for revision of the language and editing of the manuscript in its final version.

REFERENCES

Anderson, E. R., Boyle, J., Zink, W. E., Perisidkty, Y., Gendelman, H. E., and Xiong, H. (2003). Hippocampal synaptic dysfunction in a murine model of human immunodeficiency virus type 1 encephalitis. Neuroscience 118, 359–369.

Argyris, E., Acheampong, E., Wang, F., Bozyczko-Coyne, D., Saporito, M. S., Chugh, P., Fan, S., Planelles, V., Maggirwar, S. B., Uhrlaub, J. L., DeWitt, J. (2012). Improving HAART with nanoformulated strategies and delivery systems, but also an interest for adaptive treatment strategies and mathematical modeling to manage structured treatment interruptions (Rosenberg et al., 2007), have been outlined by many researchers. To this regard a tight collaboration with industry is strictly required and introduces a new set of challenges such as: (1) circulation of promising ideas, often just developed with university grants, (2) protection of intellectual property and patent rights, (3) fund-raising opportunities for start-ups during preclinical researches on novel compounds, until (4) identification of potential blockbusters appealing to Big Pharma companies for introduction in the market and their clinical exploitation.

Finally, current criteria for initiation of HAART do not consider CNS outcomes as a benchmark of efficacy, thus establishing CNS-based criteria for initiation of protocols should be the ultimate goal not only for therapeutic but also for neuroprotection strategies; as recently stated by Jeymohan et al. (2009) on behalf of the NeuroAIDS research participants these priorities should be seen as a template for future growth of the field and its long-term impact.

ACKNOWLEDGMENTS

We are grateful to Mrs. Gloria Mogren for revision of the language and editing of the manuscript in its final version.

REFERENCES

Anderson, E. R., Boyle, J., Zink, W. E., Perisidkty, Y., Gendelman, H. E., and Xiong, H. (2003). Hippocampal synaptic dysfunction in a murine model of human immunodeficiency virus type 1 encephalitis. Neurosci. 118, 359–369.

Argyris, E., Acheampong, E., Wang, F., Huang, J., Chen, K., Mukhtar, M., and Zhang, H. (2007). The IFN-γ-induced expression of APOBEC3G in human blood brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. Virology 250, 440–451.

Bansal, A. K., Mactutus, C. F., Nath, A., Maragos, W., Hauser, K. F., and Booze, R. M. (2000). Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum. Brain Res. 879, 42–49.

Barber, S. A., Uhrlahl, J. L., DeWitt, J. T., Tarwater, P. M., and Zink, M. C. (2004). Dysregulation of mitogen-activated protein kinase signaling pathways in simian immunodeficiency virus encephalitis. Am. J. Pathol. 164, 355–362.

Bissel, S. I., and Wiley, C. A. (2004). Human immunodeficiency virus infection of the brain: pitfalls in evaluating infected/affected cell populations. Brain Pathol. 14, 97–108.

Bozyczko-Coyne, D., Saporito, M. S., Chugh, P., Fan, S., Planelles, V., Maggirwar, S. B., Dewhurst, S., and Kim, B. (2008). Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology 5, 11.

Christensen, P., Fan, S., Planelles, V., Maggirwar, S. B., Dewhurst, S., and Kim, B. (2007). Infection of human immunodeficiency virus and intracellular viral Tat protein exert a pro-survival effect in human microglial cell line. J. Biol. Chem. 366, 67–81.

Cinqué, P., Previ, S., Bestetti, A., Pierotti, C., Racca, S., Boeri, E., Morelli, P., Carrera, P., Ferrari, M., and Lazzarini, A. (2001). Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid. AIDS Res. Hum. Retroviruses 17, 377–383.

Crews, L., Patrick, C., Achim, C. L., Everard, I. P., and Mushali, E. (2009). Molecular pathology of NeuroAIDS. Int. J. Mol. Sci. 10, 1045–1063.

Erdmann, W., Whitney, N., and Zheng, J. (2006). Potentiation of excitotoxicity in HIV-1 associated dementia and the significance of glutatione. Clin. Neurosci. Res. 6, 315–328.

Gissot, E., Enting, R. H., Jurriaans, S., de Wolf, F., van der Ende, M. E., Hoetelmans, R. M., Portegies, P., and Danner, S. A. (2000). Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine. AIDS 14, 1583–1589.

Jeong, Y. I., Kim, S. T., Jin, S. G., Ryu, H. H., Jin, Y. H., Jung, T. Y., Kim, Y. I., and Jung, S. (2008). Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. J. Pharm. Sci. 97, 1268–1276.

Jeymohan, J., Clifford, D., Douglas, S. D., Fox, H., Gendelman, H. E., Gonzalez-Scarano, F., Grant, I., Major, E., McArthur, J., and NeuroAIDS Research Participants. (2009). Planning future strategies for domestic and international NeuroAIDS Research. J. Neuroimmunol. Pharmaco. 4, 283–297.

Lawrence, D. M., Durham, L. C., Schwartz, L., Seth, P., Marx, D., and Major, E. O. (2004). Human immunodeficiency virus type 1 infection of human-derived progenitor cells. J. Virol. 78, 7319–7328.